Population Council

Knowledge Commons

2012

Nonclinical development needs and regulatory requirements for
multipurpose prevention technologies: A primer
Joseph W. Romano
Martha Brady
Population Council

Judy Manning

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-hiv
Part of the Health Services Research Commons, Immune System Diseases Commons, International
Public Health Commons, Medicine and Health Commons, Pharmaceutics and Drug Design Commons,
Pharmacy Administration, Policy and Regulation Commons, Virus Diseases Commons, and the Women's
Health Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Romano, Joseph W., Martha Brady, and Judy Manning. 2012. "Nonclinical development needs and
regulatory requirements for multipurpose prevention technologies: A primer." New York: Population
Council.

This Brief is brought to you for free and open access by the Population Council.

Nonclinical Development Needs and Regulatory
Requirements for Multipurpose Prevention Technologies:
A Primer
By Joe Romano, Martha Brady, and Judy Manning
As enthusiasm grows for the development of products
that address sexual and reproductive health (SRH) needs
around the world, innovative development strategies are
needed that are efficient, cost-effective, and consistent
with likely regulatory requirements for such products.
Such strategies will be even more critical as combination
products are developed that seek to address multiple
health indications simultaneously, and combine drugs and/
or devices that may be approved and/or experimental—
the prospect of which is truly a multidimensional
regulatory puzzle.

and toxicity, as well as by achieving necessary quality standards
regarding the CMC for drug substances and drug products.
We consider key development issues up through but
not including Phase I clinical studies. Clinical evaluation
strategies for MPT products will be determined by several
factors, including specific product configuration and
properties; however, these issues are beyond the scope of
this paper. Here, we focus on the nonclinical development
needs and potential regulatory requirements for MPTs.
Combination pharmaceutical products have development
and regulatory complexity beyond that of single-agent, singleindication products. The presence of more than one active
pharmaceutical ingredient (API) increases the nonclinical,
quality (CMC), and clinical development obligations for
such a product. This is further compounded when a
combination product targets more than one medical
indication, such as MPTs designed as either drug+drug or
drug+device combinations to protect against HIV, other
STIs, and unintended pregnancy (see Figure 1).

This summary outlines key development elements
necessary for various configurations of multipurpose
prevention technology (MPT) products for the
simultaneous prevention of Human Immunodeficiency
Virus (HIV), other sexually transmitted infections (STIs),
and/or pregnancy. The studies and activities described
in this summary regarding drug substances (DS) and
drug products (DP) are necessary to satisfy the content
requirements for Section 7 of an Investigational New Drug
(IND) application (Chemistry,
Manufacture, Control [CMC]).
Figure 1 MPT pathway: A typology
For an initial IND submission,
the CMC content must support
the safety of the product (purity,
stability, toxic impurities). Later
on, DS and DP manufacture will
need to satisfy International
Conference on Harmonization
(ICH) guidances Q8,1 Q9,2 and
Q10,3 which will be part of the
Quality System necessary for
commercialization.
Key elements of MPT product
development will be the assurance
of the quality and safety of DS
and DP, which can be achieved by
proper preclinical (also referred to
as nonclinical) evaluations of safety
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Product Configuration Options
Contraceptive products exist in a number of
configurations and delivery strategies, including systemic
formulations (oral pills, injectables, implants), topical
dosage forms (gels, films, vaginal rings), intrauterine devices
(with and without hormones), and physical barriers (male
and female condoms, diaphragms, cervical caps). These
products rely on either hormonal or nonhormonal API,
and achieve effect via systemic or topical delivery. Current
HIV pre-exposure prophylaxis (PrEP) products follow
similar product design options for dosing and delivery,
including systemic (oral, injectable), topical (gel, tablets,
vaginal rings), and physical barrier (diaphragm, female
condom). Although oral and topical strategies for STI
prevention exist, the development of these strategies has
not been as robust as HIV PrEP product development.

Status of selected products
A number of licensed contraceptive products exist,
including an array of hormonal products. Although no
HIV-prevention products (other than condoms) have yet
to achieve regulatory licensure, a number of antiretrovirals
(ARVs) approved for treatment of acute (post-exposure
prophylaxis [PEP]) or chronic HIV infection are in clinical
evaluation as prevention products (e.g., tenofovir,4
maraviroc5,6). However, there are a number of HIVprevention candidate products in development involving
API that have not been approved for treatment (e.g.,
MIV-150,7 dapivirine8). Similarly, some early-stage product
development efforts for new contraceptive agents (e.g.,
nonhormonal chemical entities9) are also pre-licensure.
MPT products can be developed from various combinations
of approved and/or experimental drugs and/or devices for
different single indications. The development requirements
for products that do or do not involve already approved
components will differ accordingly. In the case of MPTs,
the variable development burdens for products with API
that are in different stages of single-indication approval are
potentially complicated further if the product is configured
in a novel delivery device. For example, co-formulation
of an approved combination oral contraceptive pill with
a drug approved for treatment of HIV infection will
have different development requirements and timelines
than a vaginal ring designed to release an experimental
nonhormonal contraceptive and an experimental ARV (see
Figure 2).
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Figure 2 Optimized timelines for alternative MPT development
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Activities outlined in blue are necessary for MPT products with only approved API, or with at least one
experimental API; MPTs with at least one experimental API also require the additional activities outlined in red.

While specific development requirements will vary with each
MPT product, the broad perspectives of 1) experimental
versus approved, 2) drug versus device, and 3)
systemic versus topical delivery provide the basis for the
development of general guidelines that could help to inform
the broad spectrum of possible MPT product development
strategies.
The following sections provide a description of
development needs for possible MPT product components
in terms of nonclinical safety and quality issues.

MPT Case Study Number 1:
Co-formulation of approved drugs/
products
Nonclinical activity
Perhaps the simplest, quickest, and least expensive
MPT product development effort would involve the
co-formulation of drugs and/or devices already approved
for the different individual indications being targeted by
the combination. (Although male and female condoms
are effective HIV-prevention products, neither is currently
considered a potential component of first-generation MPT
products.) Further, because no drugs are yet approved
for prevention of HIV, first-generation MPT products will

Regulators’ primary concerns are
the potential for: 1) toxicological
and 2) pharmacokinetic (PK)
interactions. If there is experience
of co-administration, there is no
longer concern; if not, each of
these should be addressed. The
ICH guideline provides an
approach for testing the toxicology
interaction potential, and PK
assessment can be included in
these studies to identify PK
interactions. Additionally, any
product developer will want to
assess potential pharmacodynamic
(PD) interactions that may affect
dosing.

The simplest configuration of such
an MPT product would be in a
dosage/delivery form similar to that already available for
the individual product’s specific indications (e.g., oral HIV
PEP combined with an oral contraceptive). In this case,
little, if any, nonclinical safety data beyond what exists for
each individual product would likely be needed. The ICH
M3 guideline10 suggests that where there is adequate clinical
experience with co-administration of two approved late-stage
products, combination toxicity studies would generally not be
recommended to support clinical studies or marketing unless
there is significant toxicological concern (e.g., target organ
toxicity). Presumably, the individual products would have
satisfied regulatory requirements for genotoxicity, acute
and chronic toxicity, reprotoxicity, and so forth.
The proposed combination could possibly require
a nonclinical safety assessment involving fixed plus
variable doses of the two drugs in an animal system to
determine if any toxicity is potentially associated with
the combination. Alternatively, if an MPT product was
formulated for topical use (e.g., vaginal gel or ring),
additional nonclinical safety and pharmacology studies
might be required, even if the product only included API
from approved oral dosage forms. Aside from nonclinical
safety assessments, a combination product with two (or more)
approved API might also need to be evaluated from a PK
perspective in an animal model.
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The purpose of this study would be to see if the presence
of multiple drugs in the formulation had an effect on
PK or drug distribution relative to what is observed
individually with these drugs.Vaginal formulations will be
required to undergo safety and PK testing, typically in a
rabbit model system. This would likely involve alternative
dose combinations (high, medium, low doses of API1
with high, medium, low doses of API2). Additional vaginal
exposure studies may also be needed to appropriately
bridge the product formulation to data obtained from
previous studies involving oral dosing (e.g., chronic toxicity,
reprotoxicity).
Regarding efficacy, a justification for the product
components and selected doses will be necessary. This
could be achieved via a combination of in vitro, ex vivo,
and possibly in vivo animal systems. Minimally, detailed in
vitro infection studies with the ARV (or anti-STI) will be
necessary, conducted alone and possibly in combination
(depending on the product configuration) in the presence
of semen and cervical-vaginal fluids. In the case of antiHIV combination products, evaluation of efficacy in the
tissue explant model is also recommended.11 Mechanism of
action (MoA) studies from the individual approved drugs
should be adequate for the combination product. However,
studies may also be needed to evaluate the effect of the
ARV on the activity of the other component, and the effect
of the other component on the activity of the ARV.

In the case of vaginal ring delivery of combination products, a
biocompatibility program will be needed for a first-in-humans
study. This will involve a series of extraction procedures
with polar and nonpolar solvents under mild to harsh
conditions. Those extracts compatible with in vitro and in
vivo safety assessments will be tested in various systems
to determine if elements of the device, or the devicedrug(s) combination, have a potential safety risk. The
harsher condition extractions conducted with organic
solvents will be necessary to look for device material
degradation products, heavy metals, or other extractables
creating potential safety risks for the products. Specific
biocompatibility assessments need to be defined in
conjunction with regulatory agencies. Similarly, although
not necessary for Phase 1 studies with a combination
product, it will be necessary to conduct formal leachables
studies in the primary packaging for these products.

Quality

A major advantage of using approved drugs in an MPT
combination product is that the API material has satisfied
all quality requirements (i.e. CMC). Thus, the good
manufacturing practice (GMP) as well as necessary
analytical methods for material analysis (e.g., release and
stability testing) have been adequately validated. IND
applications for MPT products using approved drugs
should be able to cross-reference the approved new
drug application (NDA) for the
API (similar to the process used
Figure 3 Potential studies to be initiated during development phases
to reference the approved API
nonclinical and clinical data).
Nonclinical Development

Clinical Phases

Commercialization

ADME

(Association of Destination Management Executives)

DMPK

(drug metabolism and pharmacokinetic)

Pharmacology
Genetic toxicology
General toxicity
Immunotoxicity
Reproductive toxicology
Immunogenicity
Bioassay
Microbiology

Source: Eurofins, “Integrated approach of drug development.” http://www.eurofins.com/
pharma-services/pharma-early-development.aspx. Accessed 26 September 2012.

Combination MPT products
will involve novel formulation
development. The entire DP section
of the IND (Section 7.2) will need
to be generated. Use of approved
drugs in the MPT product will not
reduce the development effort or
regulatory burden associated with
the final product formulation. The
quality requirements for an MPT
product will be similar to those
required for single-agent, singleindication products. However,
there will likely be greater
complexity on the technical
development of manufacturing
processes and analytical methods.
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The nature of the requirements will be a function of the
product’s stage of development. As the MPT product
advances from Phase 1 through Phase 3 and on to
an NDA, the quality requirements will increase and
become more stringent. For early clinical work (Phase
1), some of the major requirements include: formulation
composition, excipient quality, manufacturing process and
control, packaging, initial product specifications, qualified
analytical methods for release and stability testing,
stability data from multiple batches, and a certificate of
analysis for clinical supplies. As the process and methods
become more refined through continued development
of the DP, any changes and validations will need to be
documented and described. Any excipient changes (new
excipients or new raw materials sources) will need to
be described and qualified. Additional stability data will
need to be reported as well. As the product progresses
to Phase 3, the specification limits must be narrowed
and justified. Additional assessments will include: physical
chemical characterization, finalization of container
closure, definition of critical process parameters for
design of experiment (DOE)-based quality by design
(QBD) manufacturing,1,2,3 validation batch production
and characterization, and so forth. In addition to the drug
product material requirements, it will be necessary to
develop and validate equipment cleaning procedures for
the manufacturing equipment that produces the drug
product.

MPT Case Study Number 2:
Combination products that include one
or more experimental drugs and/or
devices
Using experimental components in a new MPT product
will require significantly more nonclinical and qualityrelated efforts. Typically, an experimental API, or new drug
entity (NDE), is progressed through nonclinical evaluations
in parallel with quality-related development. Toxicological
or other issues may be identified, requiring additional
follow-up studies that add cost and time to the
development program. In some cases, this could result in
“no go” development decisions for a product. Developing
MPTs with one or more NDEs has inherently more risk
and expense. This additional risk dictates the need for
comprehensive nonclinical assessments and detailed quality
evaluations so that major impediments to development
can be identified early on, potentially saving significant

effort and investment in products that are not appropriate
as MPT candidates.
Nonclinical evaluation of MPT products with
experimental components will require a range of
nonclinical studies depending on the indication,
route of administration, and physical-chemical
properties of the drug and/or device. In the case
of anti-HIV compounds, nonclinical virology studies
will be needed. These typically include in vitro effective
concentration (EC50) determinations for lab-adapted
strains as well as with primary viral isolates across viral
clades in peripheral blood mononuclear cells (PBMC).
Other specialized assays (e.g., dendritic cell model) as well
as ex vivo (human explant tissue) and in vivo (e.g., nonhuman
primate) models may be part of the virology package.
MoA characterization will be required as will studies
looking at the development of resistance. A complete
safety pharmacology package will also be required. The scope
of this package will depend on whether or not the drug is
administered systemically or topically (and if administered
topically, how much absorption is achieved). Secondary
pharmacology studies looking at other targets (e.g.,
enzymes, ion channels, receptors) are typically required
as well. Genotoxicity will need to be assessed with at
least two methods; specific systems to be evaluated might
include central nervous system, cardiovascular, and/or
respiratory. These assessments can be made by individual
studies, or as part of a panel of more general studies
including single and repeat dose toxicology studies, dose
ranging studies, and long-term chronic toxicity studies (e.g.,
six months in dogs, nine months in rabbits). The need for
and nature of these studies will be determined by data
obtained through the course and stage of development,
and the intended route of administration.

Importance of PK Studies
PK studies in animals are necessary for several
reasons. They confirm the level of drug exposure, assuring
that safety is established in the presence of the drug. They
also help validate the species used in the preclinical
investigations by confirming that the pharmacokinetic
profiles are similar to that observed with humans. In
addition, these studies enable safety margins to be
established based on the higher exposures achieved in
animals versus those seen in humans. In the case of MPTs,
PK studies can also help define whether any interactions
between APIs alter the way they are absorbed, distributed,
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metabolized, or excreted from the body that may need
to be addressed in product design. The extent of PK work
necessary will depend on the route of administration of the
product and the extent to which the APIs are absorbed.
A PK package will be necessary, including single and repeat
dose studies conducted in multiple species with plasma and
tissue drug level determinations. These studies will involve
standard calculations of such parameters as maximum
concentration (Cmax), time to maximum concentration
(Tmax), area under curve (AUC), and time to 50 percent
reduction (T1/2). Repeat dose PK can be evaluated during
toxicology studies. Distribution studies at some level
will likely be required (e.g., whole body autoradiography
with radiolabeled drug); however, specific metabolism and
elimination study requirements will depend on the drug,
route of administration, absorption, and PK profiles.
Specialized toxicology studies will be needed for MPT
products, including reprotoxicity (segments 1, 2, and 3),
guinea pig sensitization, and other assessments depending
on the drug and product configuration. This may include
the biocompatibility types of studies described earlier
for device-based delivery. Finally, NDE will require
carcinogenicity studies in one or two species.
It is not possible to predesign a complete nonclinical package
for NDE that would be necessary for NDA approval. The
above summary of potential studies outlines what might
be part of a typical NDE nonclinical package. Additional
guidance is available12 for the nonclinical evaluation of
microbicide-type products that may be useful for certain
MPT products. However, the specific studies needed to
support a product are to a significant degree determined
through the course of the overall development of the
product. Ultimately, the necessary nonclinical studies for
a given product are determined through interactions with
regulatory authorities.

NDE quality
The same drug product requirements discussed earlier
for an MPT drug product involving approved drugs would
apply to a formulated product achieved with NDE(s)
as the API(s). The major difference in quality requirements
for an MPT using an approved drug and an MPT using an
NDE is at the level of the drug substance. Approved drugs
presumably have the benefit of a full drug substance
quality package; experimental drugs need to generate such
a package through the course of product development.

Depending on the nature of the NDE, the drug substance
quality packages could vary significantly. For example, the
requirements for a small organic molecule will be quite
different than those of a recombinant protein API. The
requirements of either of these types of entity would
differ even further from a probiotic product. Thus, it is
difficult to provide a comprehensive overview of drug
substance quality requirements for all possible MPT
options. Minimally, a quality package for a small organic
molecule API would likely require physical-chemical
characterization, solubility profiles, stability assessments
under different conditions (e.g., temperature, moisture,
light, oxidation, etc.), route of synthesis definition, analytical
methods development and validation, process scale up, and
specifications with justifications. Other more specialized
characterizations could include polymorph definition,
sterility (if needed), and microbe testing. As in the case of
drug product manufacture, experimental API production
will involve definition of critical process parameters, and
DOE-type process development for QBD production at
commercial scale. Multiple batches of the experimental
API with full stability assessments will be required, as will
validation batch production and characterization. Packaging
and container closure will need to be addressed for API,
similar to what was described for the drug product.
MPT products can be configured with device
technologies either as a means of achieving active
drug delivery or as a means of directly achieving
efficacy for one or more intended indications. Vaginal
ring products described earlier serve as the most
common example of MPT products where the device
serves exclusively as the means of delivering the active
pharmaceutical agents necessary for the dual indication
efficacies. Typically, regulatory review of such products
is achieved from the perspective of the active drugs, not
the delivery mechanism. For example, primary review at
the U. S. Food and Drug Administration (FDA) of a vaginal
ring delivering an antiviral and hormonal contraceptive
would likely occur with the Center for Drug Evaluation
and Research (CDER). However, additional review of such
a product would be provided by the Center for Devices
and Radiological Health (CDRH). Alternatively, a device
responsible directly for an efficacy outcome could be
reviewed primarily by CDRH. Agency guidance for barrier
devices for contraception and STI prevention are available
via the CDRH.13
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Summary
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